To date there is no evidence-based medical intervention to help patients with persistent dysosmia due to COVID-19, although olfactory training (OT) has been recommended. Permanent olfactory loss may lead many to suffer from known comorbidities, such as depression and impaired cognition, and even maybe from earlier death. Even a small proportion of affected patients may number in the tens of thousands in the case of COVID-19. This is already known to be the case for patients with an upper respiratory infection caused by viruses such as parainfluenza, rhinovirus, or other coronaviruses. As they pointed out, though most patients should make a full recovery, it is likely that a certain proportion of them will develop permanent post-viral olfactory dysfunction (PVOD). found that olfactory function was more affected in patients with COVID-19 than those with common cold. Loss of smell due to COVID-19 may be more prevalent and severe than in other viral upper respiratory infections. Studies relying on more reliable data, such as psychophysical testing, showed persistent abnormal olfactory scores in 37% to 52% of patients 5 weeks after onset. The clinical evolution of loss of smell due to COVID-19 is still unclear as reports of recovery vary significantly, ranging from 4 to 89% a month after the onset of anosmia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |